P50: A candidate ERP biomarker of prodromal Alzheimer's disease

Deborah L. Green; Lisa Payne; Robi Polikar; Paul J. Moberg; David A. Wolk; John Kounios

doi:10.1016/j.brainres.2015.07.054

P50: A candidate ERP biomarker of prodromal Alzheimer's disease

Deborah L. Green, Lisa Payne, Robi Polikar, Paul J. Moberg, David A. Wolk, John Kounios

Research output: Contribution to journal › Article › peer-review

20 Scopus citations

Abstract

Introduction Reductions of cerebrospinal fluid (CSF) amyloid-beta (Aβ42) and elevated phosphorylated-tau (p-Tau) reflect in vivo Alzheimer's disease (AD) pathology and show utility in predicting conversion from mild cognitive impairment (MCI) to dementia. We investigated the P50 event-related potential component as a noninvasive biomarker of AD pathology in non-demented elderly. Methods 36 MCI patients were stratified into amyloid positive (MCI-AD, n=17) and negative (MCI-Other, n=19) groups using CSF levels of Aβ42. All amyloid positive patients were also p-Tau positive. P50s were elicited with an auditory oddball paradigm. Results MCI-AD patients yielded larger P50s than MCI-Other. The best amyloid-status predictor model showed 94.7% sensitivity, 94.1% specificity and 94.4% total accuracy. Discussion P50 predicted amyloid status in MCI patients, thereby showing a relationship with AD pathology versus MCI from another etiology. The P50 may have clinical utility for inexpensive pre-screening and assessment of Alzheimer's pathology.

Original language	English (US)
Pages (from-to)	390-397
Number of pages	8
Journal	Brain Research
Volume	1624
DOIs	https://doi.org/10.1016/j.brainres.2015.07.054
State	Published - 2015
Externally published	Yes

All Science Journal Classification (ASJC) codes

General Neuroscience
Molecular Biology
Clinical Neurology
Developmental Biology

Access to Document

10.1016/j.brainres.2015.07.054

Cite this

@article{af76bb19c6654aa08fb40c3c6e11d3b1,

title = "P50: A candidate ERP biomarker of prodromal Alzheimer's disease",

abstract = "Introduction Reductions of cerebrospinal fluid (CSF) amyloid-beta (Aβ42) and elevated phosphorylated-tau (p-Tau) reflect in vivo Alzheimer's disease (AD) pathology and show utility in predicting conversion from mild cognitive impairment (MCI) to dementia. We investigated the P50 event-related potential component as a noninvasive biomarker of AD pathology in non-demented elderly. Methods 36 MCI patients were stratified into amyloid positive (MCI-AD, n=17) and negative (MCI-Other, n=19) groups using CSF levels of Aβ42. All amyloid positive patients were also p-Tau positive. P50s were elicited with an auditory oddball paradigm. Results MCI-AD patients yielded larger P50s than MCI-Other. The best amyloid-status predictor model showed 94.7% sensitivity, 94.1% specificity and 94.4% total accuracy. Discussion P50 predicted amyloid status in MCI patients, thereby showing a relationship with AD pathology versus MCI from another etiology. The P50 may have clinical utility for inexpensive pre-screening and assessment of Alzheimer's pathology.",

author = "Green, {Deborah L.} and Lisa Payne and Robi Polikar and Moberg, {Paul J.} and Wolk, {David A.} and John Kounios",

note = "Funding Information: This work was supported by a Health Research Grant [Grant number SAP4100027296 ] awarded by the Department of Health of the Commonwealth of Pennsylvania from the Tobacco Master Settlement Agreement under Act 2001-77. We would like to acknowledge the late Christopher M. Clark, M.D., as the principal investigator to whom this funding was awarded for the parent study Biomarkers of Late Life Dementia conducted at the University of Pennsylvania, Philadelphia, PA, USA.",

year = "2015",

doi = "10.1016/j.brainres.2015.07.054",

language = "English (US)",

volume = "1624",

pages = "390--397",

journal = "Brain Research",

issn = "0006-8993",

publisher = "Elsevier B.V.",

}

TY - JOUR

T1 - P50

T2 - A candidate ERP biomarker of prodromal Alzheimer's disease

AU - Green, Deborah L.

AU - Payne, Lisa

AU - Polikar, Robi

AU - Moberg, Paul J.

AU - Wolk, David A.

AU - Kounios, John

N1 - Funding Information: This work was supported by a Health Research Grant [Grant number SAP4100027296 ] awarded by the Department of Health of the Commonwealth of Pennsylvania from the Tobacco Master Settlement Agreement under Act 2001-77. We would like to acknowledge the late Christopher M. Clark, M.D., as the principal investigator to whom this funding was awarded for the parent study Biomarkers of Late Life Dementia conducted at the University of Pennsylvania, Philadelphia, PA, USA.

PY - 2015

Y1 - 2015

N2 - Introduction Reductions of cerebrospinal fluid (CSF) amyloid-beta (Aβ42) and elevated phosphorylated-tau (p-Tau) reflect in vivo Alzheimer's disease (AD) pathology and show utility in predicting conversion from mild cognitive impairment (MCI) to dementia. We investigated the P50 event-related potential component as a noninvasive biomarker of AD pathology in non-demented elderly. Methods 36 MCI patients were stratified into amyloid positive (MCI-AD, n=17) and negative (MCI-Other, n=19) groups using CSF levels of Aβ42. All amyloid positive patients were also p-Tau positive. P50s were elicited with an auditory oddball paradigm. Results MCI-AD patients yielded larger P50s than MCI-Other. The best amyloid-status predictor model showed 94.7% sensitivity, 94.1% specificity and 94.4% total accuracy. Discussion P50 predicted amyloid status in MCI patients, thereby showing a relationship with AD pathology versus MCI from another etiology. The P50 may have clinical utility for inexpensive pre-screening and assessment of Alzheimer's pathology.

AB - Introduction Reductions of cerebrospinal fluid (CSF) amyloid-beta (Aβ42) and elevated phosphorylated-tau (p-Tau) reflect in vivo Alzheimer's disease (AD) pathology and show utility in predicting conversion from mild cognitive impairment (MCI) to dementia. We investigated the P50 event-related potential component as a noninvasive biomarker of AD pathology in non-demented elderly. Methods 36 MCI patients were stratified into amyloid positive (MCI-AD, n=17) and negative (MCI-Other, n=19) groups using CSF levels of Aβ42. All amyloid positive patients were also p-Tau positive. P50s were elicited with an auditory oddball paradigm. Results MCI-AD patients yielded larger P50s than MCI-Other. The best amyloid-status predictor model showed 94.7% sensitivity, 94.1% specificity and 94.4% total accuracy. Discussion P50 predicted amyloid status in MCI patients, thereby showing a relationship with AD pathology versus MCI from another etiology. The P50 may have clinical utility for inexpensive pre-screening and assessment of Alzheimer's pathology.

UR - http://www.scopus.com/inward/record.url?scp=84954285919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954285919&partnerID=8YFLogxK

U2 - 10.1016/j.brainres.2015.07.054

DO - 10.1016/j.brainres.2015.07.054

M3 - Article

C2 - 26256251

AN - SCOPUS:84954285919

SN - 0006-8993

VL - 1624

SP - 390

EP - 397

JO - Brain Research

JF - Brain Research

ER -

P50: A candidate ERP biomarker of prodromal Alzheimer's disease

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this